Acute Mood-Elevating Properties of Microdosed Lysergic Acid Diethylamide in Healthy Volunteers : A Home-Administered Randomized Controlled Trial
Copyright © 2023 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Microdosing psychedelic drugs is a widespread social phenomenon with diverse benefits claimed for mood and cognition. Randomized controlled trials have failed to support these claims, but the laboratory-based dosing in trials conducted to date may have limited ecological validity.
METHODS: Healthy male volunteers were randomized into lysergic acid diethylamide (LSD) (n = 40) and placebo (n = 40) groups and received 14 doses of either 10 μg LSD or an inactive placebo every 3 days for 6 weeks. First doses were given in a supervised laboratory setting, with other doses self-administered in a naturalistic setting. Results of safety data, blinding, daily questionnaires, expectancy, and pre-/postintervention psychometrics and cognitive tasks are presented here.
RESULTS: The most notable reported adverse event was treatment-related anxiety, which prompted the withdrawal of 4 participants from the LSD group. Daily questionnaires showed credible evidence (>99% posterior probability) of improved ratings of creativity, connectedness, energy, happiness, irritability, and wellness on dose days compared with nondose days, and these effects remained when controlling for preintervention expectancy. No questionnaire or cognitive task showed a credible change between baseline and 6-week assessment time points.
CONCLUSIONS: Microdosing LSD appears to be relatively safe in healthy adult men, notwithstanding a risk of anxiety. While microdosing elicited transient increases in scales associated with mood-elevating effects, it was not sufficient to promote enduring changes to overall mood or cognition in healthy adults. Future microdosing trials in clinical populations will require the use of active placebos to control for placebo effects and dose titration to adjust for interindividual variability in drug response.
| Errataetall: |
CommentIn: Biol Psychiatry. 2023 Sep 15;94(6):e23-e24. - PMID 37611985 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:94 |
|---|---|
| Enthalten in: |
Biological psychiatry - 94(2023), 6 vom: 15. Sept., Seite 511-521 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Murphy, Robin J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
8NA5SWF92O |
|---|
| Anmerkungen: |
Date Completed 25.08.2023 Date Revised 28.08.2023 published: Print-Electronic CommentIn: Biol Psychiatry. 2023 Sep 15;94(6):e23-e24. - PMID 37611985 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.biopsych.2023.03.013 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355019892 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355019892 | ||
| 003 | DE-627 | ||
| 005 | 20231226063451.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biopsych.2023.03.013 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1183.xml |
| 035 | |a (DE-627)NLM355019892 | ||
| 035 | |a (NLM)36997080 | ||
| 035 | |a (PII)S0006-3223(23)01164-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Murphy, Robin J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Acute Mood-Elevating Properties of Microdosed Lysergic Acid Diethylamide in Healthy Volunteers |b A Home-Administered Randomized Controlled Trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.08.2023 | ||
| 500 | |a Date Revised 28.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Biol Psychiatry. 2023 Sep 15;94(6):e23-e24. - PMID 37611985 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Microdosing psychedelic drugs is a widespread social phenomenon with diverse benefits claimed for mood and cognition. Randomized controlled trials have failed to support these claims, but the laboratory-based dosing in trials conducted to date may have limited ecological validity | ||
| 520 | |a METHODS: Healthy male volunteers were randomized into lysergic acid diethylamide (LSD) (n = 40) and placebo (n = 40) groups and received 14 doses of either 10 μg LSD or an inactive placebo every 3 days for 6 weeks. First doses were given in a supervised laboratory setting, with other doses self-administered in a naturalistic setting. Results of safety data, blinding, daily questionnaires, expectancy, and pre-/postintervention psychometrics and cognitive tasks are presented here | ||
| 520 | |a RESULTS: The most notable reported adverse event was treatment-related anxiety, which prompted the withdrawal of 4 participants from the LSD group. Daily questionnaires showed credible evidence (>99% posterior probability) of improved ratings of creativity, connectedness, energy, happiness, irritability, and wellness on dose days compared with nondose days, and these effects remained when controlling for preintervention expectancy. No questionnaire or cognitive task showed a credible change between baseline and 6-week assessment time points | ||
| 520 | |a CONCLUSIONS: Microdosing LSD appears to be relatively safe in healthy adult men, notwithstanding a risk of anxiety. While microdosing elicited transient increases in scales associated with mood-elevating effects, it was not sufficient to promote enduring changes to overall mood or cognition in healthy adults. Future microdosing trials in clinical populations will require the use of active placebos to control for placebo effects and dose titration to adjust for interindividual variability in drug response | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Anxiety | |
| 650 | 4 | |a Cognition | |
| 650 | 4 | |a LSD | |
| 650 | 4 | |a Microdosing | |
| 650 | 4 | |a Mood | |
| 650 | 4 | |a Psychedelics | |
| 650 | 7 | |a Hallucinogens |2 NLM | |
| 650 | 7 | |a Lysergic Acid Diethylamide |2 NLM | |
| 650 | 7 | |a 8NA5SWF92O |2 NLM | |
| 700 | 1 | |a Sumner, Rachael |e verfasserin |4 aut | |
| 700 | 1 | |a Evans, William |e verfasserin |4 aut | |
| 700 | 1 | |a Ponton, Rhys |e verfasserin |4 aut | |
| 700 | 1 | |a Ram, Sanya |e verfasserin |4 aut | |
| 700 | 1 | |a Godfrey, Kate |e verfasserin |4 aut | |
| 700 | 1 | |a Forsyth, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Cavadino, Alana |e verfasserin |4 aut | |
| 700 | 1 | |a Krishnamurthy Naga, Venkat |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Todd |e verfasserin |4 aut | |
| 700 | 1 | |a Hoeh, Nicholas R |e verfasserin |4 aut | |
| 700 | 1 | |a Menkes, David B |e verfasserin |4 aut | |
| 700 | 1 | |a Muthukumaraswamy, Suresh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biological psychiatry |d 1969 |g 94(2023), 6 vom: 15. Sept., Seite 511-521 |w (DE-627)NLM000098140 |x 1873-2402 |7 nnns |
| 773 | 1 | 8 | |g volume:94 |g year:2023 |g number:6 |g day:15 |g month:09 |g pages:511-521 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.biopsych.2023.03.013 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 94 |j 2023 |e 6 |b 15 |c 09 |h 511-521 | ||